Pain-relieving prospects for adenosine receptors and ectonucleotidases

Trends in Molecular Medicine

Volumn 17, Issue 4, 2011, Pages 188-196

  Zylka, Mark J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 5 IODOTUBERCIDIN; ACID PHOSPHATASE PROSTATE ISOENZYME; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE PHOSPHATE; ADENOSINE RECEPTOR; ATL 313; BVT 115959; CLONIDINE; CVT 3619; ECTO 5' NUCLEOTIDASE; ECTONUCLEOTIDASE; GW 493838; INO 8875; PENTOSTATIN; T 62; TRIPHOSPHOINOSITIDE; UNCLASSIFIED DRUG; VESICULAR GLUTAMATE TRANSPORTER;

ALLODYNIA; ANALGESIC ACTIVITY; ATRIOVENTRICULAR BLOCK; BACKACHE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYPERALGESIA; NEUROPATHIC PAIN; NONHUMAN; PAIN; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PROTEIN FUNCTION; RECEPTOR INTRINSIC ACTIVITY; REVIEW;

5'-NUCLEOTIDASE; ACUPUNCTURE THERAPY; ADENOSINE; ADENOSINE MONOPHOSPHATE; ANALGESICS; ANIMALS; HUMANS; HYPERALGESIA; INFLAMMATION; NEURALGIA; NOCICEPTORS; PROTEIN TYROSINE PHOSPHATASES; PURINERGIC P1 RECEPTOR AGONISTS; RECEPTORS, PURINERGIC P1; RECOMBINANT PROTEINS;

EID: 79954578322     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2010.12.006     Document Type: Review

References (94)

1. Jacobson K.A., Gao Z.G. Adenosine receptors as therapeutic targets. Nat. Rev. Drug Discov. 2006, 5:247-264.
2. Schulte G., et al. Distribution of antinociceptive adenosine A1 receptors in the spinal cord dorsal horn, and relationship to primary afferents and neuronal subpopulations. Neuroscience 2003, 121:907-916.
3. Reppert S.M., et al. Molecular cloning and characterization of a rat A1-adenosine receptor that is widely expressed in brain and spinal cord. Mol. Endocrinol. 1991, 5:1037-1048.
4. Lima F.O., et al. Direct blockade of inflammatory hypernociception by peripheral A1 adenosine receptors: Involvement of the NO/cGMP/PKG/KATP signaling pathway. Pain 2010, 151:506-515.
5. Sawynok J. Adenosine and ATP receptors. Handb. Exp. Pharmacol. 2007, 177:309-328.
6. Hayashida M., et al. Clinical application of adenosine and ATP for pain control. J. Anesth. 2005, 19:225-235.
7. Lynch M.E., et al. Intravenous adenosine alleviates neuropathic pain: a double blind placebo controlled crossover trial using an enriched enrolment design. Pain 2003, 103:111-117.
8. Karlsten R., Gordh T. An A1-selective adenosine agonist abolishes allodynia elicited by vibration and touch after intrathecal injection. Anesth. Analg. 1995, 80:844-847.
9. Eisenach J.C., et al. Intrathecal but not intravenous opioids release adenosine from the spinal cord. J. Pain 2004, 5:64-68.
10. Lind G., et al. Drug-enhanced spinal stimulation for pain: a new strategy. Acta Neurochir. Suppl. 2007, 97:57-63.
11. Taiwo Y.O., Levine J.D. Direct cutaneous hyperalgesia induced by adenosine. Neuroscience 1990, 38:757-762.
12. Backonja M.M., Stacey B. Neuropathic pain symptoms relative to overall pain rating. J. Pain 2004, 5:491-497.
13. King T., et al. Unmasking the tonic-aversive state in neuropathic pain. Nat. Neurosci. 2009, 12:1364-1366.
14. Dolphin A.C., et al. Calcium-dependent currents in cultured rat dorsal root ganglion neurones are inhibited by an adenosine analogue. J. Physiol. 1986, 373:47-61.
15. Mynlieff M., Beam K.G. Adenosine acting at an A1 receptor decreases N-type calcium current in mouse motoneurons. J. Neurosci. 1994, 14:3628-3634.
16. Schmidtko A., et al. Ziconotide for treatment of severe chronic pain. Lancet 2010, 375:1569-1577.
17. Martin T.J., et al. Opioid self-administration in the nerve-injured rat: relevance of antiallodynic effects to drug consumption and effects of intrathecal analgesics. Anesthesiology 2007, 106:312-322.
18. Eisenach J.C., et al. Intrathecal, but not intravenous adenosine reduces allodynia in patients with neuropathic pain. Pain 2003, 105:65-70.
19. Zahn P.K., et al. Adenosine A1 but not A2a receptor agonist reduces hyperalgesia caused by a surgical incision in rats: a pertussis toxin-sensitive G protein-dependent process. Anesthesiology 2007, 107:797-806.
20. Basbaum A.I., et al. Cellular and molecular mechanisms of pain. Cell 2009, 139:267-284.
21. Langford D.J., et al. Coding of facial expressions of pain in the laboratory mouse. Nat. Methods 2010, 7:447-449.
22. Gan T.J., Habib A.S. Adenosine as a non-opioid analgesic in the perioperative setting. Anesth. Analg. 2007, 105:487-494.
23. Habib A.S., et al. Phase 2, double-blind, placebo-controlled, dose-response trial of intravenous adenosine for perioperative analgesia. Anesthesiology 2008, 109:1085-1091.
24. Sowa N.A., et al. Prostatic acid phosphatase reduces thermal sensitivity and chronic pain sensitization by depleting phosphatidylinositol 4,5-bisphosphate. J. Neurosci. 2010, 30:10282-10293.
25. Ji R.R., et al. MAP kinase and pain. Brain Res. Rev. 2009, 60:135-148.
26. Matsuka Y., et al. Altered ATP release and metabolism in dorsal root ganglia of neuropathic rats. Mol. Pain 2008, 4:66.
27. Dixon C.J., et al. Regulation of epidermal homeostasis through P2Y2 receptors. Br. J. Pharmacol. 1999, 127:1680-1686.
28. Koizumi S., et al. Ca2+ waves in keratinocytes are transmitted to sensory neurons: the involvement of extracellular ATP and P2Y2 receptor activation. Biochem. J. 2004, 380:329-338.
29. Nakamura F., Strittmatter S.M. P2Y1 purinergic receptors in sensory neurons: contribution to touch-induced impulse generation. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:10465-10470.
30. Gourine A.V., et al. Astrocytes control breathing through pH-dependent release of ATP. Science 2010, 329:571-575.
31. Arcuino G., et al. Intercellular calcium signaling mediated by point-source burst release of ATP. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:9840-9845.
32. Lin J.H., et al. A central role of connexin 43 in hypoxic preconditioning. J. Neurosci. 2008, 28:681-695.
33. Kang J., et al. Connexin 43 hemichannels are permeable to ATP. J. Neurosci. 2008, 28:4702-4711.
34. Sabirov R.Z., Okada Y. ATP release via anion channels. Purinergic Signal. 2005, 1:311-328.
35. Sawada K., et al. Identification of a vesicular nucleotide transporter. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:5683-5686.
36. Fields R.D., Ni Y. Nonsynaptic communication through ATP release from volume-activated anion channels in axons. Sci. Signal. 2010, 3:ra73.
37. Sreedharan S., et al. Glutamate, aspartate and nucleotide transporters in the SLC17 family form four main phylogenetic clusters: evolution and tissue expression. BMC Genomics 2010, 11:17.
38. Zimmermann H. Ectonucleotidases in the nervous system. Novartis Found. Symp. 2006, 276:113-128.
39. Dunwiddie T.V., et al. Adenine nucleotides undergo rapid, quantitative conversion to adenosine in the extracellular space in rat hippocampus. J. Neurosci. 1997, 17:7673-7682.
40. Nakagawa T., et al. Intrathecal administration of ATP produces long-lasting allodynia in rats: differential mechanisms in the phase of the induction and maintenance. Neuroscience 2007, 147:445-455.
41. Tsuda M., et al. Neuropathic pain and spinal microglia: a big problem from molecules in " small" glia. Trends Neurosci. 2005, 28:101-107.
42. Gereau R.W., Conn P.J. Potentiation of cAMP responses by metabotropic glutamate receptors depresses excitatory synaptic transmission by a kinase-independent mechanism. Neuron 1994, 12:1121-1129.
43. Brundege J.M., et al. The role of cyclic AMP as a precursor of extracellular adenosine in the rat hippocampus. Neuropharmacology 1997, 36:1201-1210.
44. Sawynok J., Liu X.J. Adenosine in the spinal cord and periphery: release and regulation of pain. Prog. Neurobiol. 2003, 69:313-340.
45. Kowaluk E.A., Jarvis M.F. Therapeutic potential of adenosine kinase inhibitors. Expert Opin. Investig. Drugs 2000, 9:551-564.
46. McGaraughty S., et al. Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors. Curr. Top. Med. Chem. 2005, 5:43-58.
47. Zylka M.J., et al. Prostatic acid phosphatase is an ectonucleotidase and suppresses pain by generating adenosine. Neuron 2008, 60:111-122.
48. Taylor-Blake B., Zylka M.J. Prostatic acid phosphatase is expressed in peptidergic and nonpeptidergic nociceptive neurons of mice and rats. PLoS One 2010, 5:e8674.
49. Sowa N.A., et al. Ecto-5'-nucleotidase (CD73) inhibits nociception by hydrolyzing AMP to adenosine in nociceptive circuits. J. Neurosci. 2010, 30:2235-2244.
50. Sweeney M.I., et al. Morphine, capsaicin and K+ release purines from capsaicin-sensitive primary afferent nerve terminals in the spinal cord. J. Pharmacol. Exp. Ther. 1989, 248:447-454.
51. Torres I.L., et al. Effect of chronic and acute stress on ectonucleotidase activities in spinal cord. Physiol. Behav. 2002, 75:1-5.
52. Patterson S.L., et al. A novel transverse push-pull microprobe: in vitro characterization and in vivo demonstration of the enzymatic production of adenosine in the spinal cord dorsal horn. J. Neurochem. 2001, 76:234-246.
53. Sowa N.A., et al. Recombinant ecto-5'-nucleotidase (CD73) has long lasting antinociceptive effects that are dependent on adenosine A1 receptor activation. Mol. Pain 2010, 6:20.
54. Wu W.P., et al. Increased nociceptive response in mice lacking the adenosine A1 receptor. Pain 2005, 113:395-404.
55. Keil G.J., DeLander G.E. Altered sensory behaviors in mice following manipulation of endogenous spinal adenosine neurotransmission. Eur. J. Pharmacol. 1996, 312:7-14.
56. Tian L., et al. Excitatory synaptic transmission in the spinal substantia gelatinosa is under an inhibitory tone of endogenous adenosine. Neurosci. Lett. 2010, 477:28-32.
57. Rozisky J.R., et al. Neonatal morphine exposure alters E-NTPDase activity and gene expression pattern in spinal cord and cerebral cortex of rats. Eur. J. Pharmacol. 2010, 642:72-76.
58. Sowa N.A., et al. Recombinant mouse PAP has pH-dependent ectonucleotidase activity and acts through A1-adenosine receptors to mediate antinociception. PLoS One 2009, 4:e4248.
59. Zimmermann H. Prostatic acid phosphatase, a neglected ectonucleotidase. Purinergic Signal. 2009, 5:273-275.
60. Millan J.L. Alkaline phosphatases: structure, substrate specificity and functional relatedness to other members of a large superfamily of enzymes. Purinergic Signal. 2006, 2:335-341.
61. Vihko P., et al. Secretion into and elimination from blood circulation of prostate specific acid phosphatase, measured by radioimmunoassay. J. Urol. 1982, 128:202-204.
62. Williams J.A., et al. Ziconotide: an update and review. Expert Opin. Pharmacother. 2008, 9:1575-1583.
63. Post C. Antinociceptive effects in mice after intrathecal injection of 5'-N-ethylcarboxamide adenosine. Neurosci. Lett. 1984, 51:325-330.
64. Sklar S.H., et al. Herpes zoster. The treatment and prevention of neuralgia with adenosine monophosphate. J. Am. Med. Assoc. 1985, 253:1427-1430.
65. El-Tayeb A., et al. Nucleoside-5'-monophosphates as prodrugs of adenosine A2A receptor agonists activated by ecto-5'-nucleotidase. J. Med. Chem. 2009, 52:7669-7677.
66. Boyer J.L., et al. Identification of potent P2Y-purinoceptor agonists that are derivatives of adenosine 5'-monophosphate. Br. J. Pharmacol. 1996, 118:1959-1964.
67. Malin S.A., Molliver D.C. Gi- and Gq-coupled ADP (P2Y) receptors act in opposition to modulate nociceptive signaling and inflammatory pain behavior. Mol. Pain 2010, 6:21.
68. Zhang J., et al. Constant darkness is a circadian metabolic signal in mammals. Nature 2006, 439:340-343.
69. Daniels I.S., et al. A role of erythrocytes in adenosine monophosphate initiation of hypometabolism in mammals. J. Biol. Chem. 2010, 285:20716-20723.
70. Swoap S.J., et al. AMP does not induce torpor. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 293:R468-R473.
71. Zhao Z.Q. Neural mechanism underlying acupuncture analgesia. Prog. Neurobiol. 2008, 85:355-375.
72. Ernst E. Acupuncture: what does the most reliable evidence tell us?. J. Pain Symptom Manage. 2009, 37:709-714.
73. Goldman N., et al. Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture. Nat. Neurosci. 2010, 13:883-888.
74. Aley K.O., Levine J.D. Multiple receptors involved in peripheral alpha 2, mu, and A1 antinociception, tolerance, and withdrawal. J. Neurosci. 1997, 17:735-744.
75. Liu C., et al. Involvement of purines in analgesia produced by weak electro-acupuncture. Zhen Ci Yan Jiu 1994, 19:59-62. 54.
76. Zylka M.J. Needling adenosine receptors for pain relief. Nat. Neurosci. 2010, 13:783-784.
77. Rohacs T., et al. Phospholipase C mediated modulation of TRPV1 channels. Mol. Neurobiol. 2008, 37:153-163.
78. Loram L.C., et al. Enduring reversal of neuropathic pain by a single intrathecal injection of adenosine 2A receptor agonists: a novel therapy for neuropathic pain. J. Neurosci. 2009, 29:14015-14025.
79. Lee Y.W., Yaksh T.L. Pharmacology of the spinal adenosine receptor which mediates the antiallodynic action of intrathecal adenosine agonists. J. Pharmacol. Exp. Ther. 1996, 277:1642-1648.
80. Poon A., Sawynok J. Antinociception by adenosine analogs and inhibitors of adenosine metabolism in an inflammatory thermal hyperalgesia model in the rat. Pain 1998, 74:235-245.
81. Orr A.G., et al. Adenosine A2A receptor mediates microglial process retraction. Nat. Neurosci. 2009, 12:872-878.
82. Colgan S.P., et al. Physiological roles for ecto-5'-nucleotidase (CD73). Purinergic Signal. 2006, 2:351-360.
83. Quintero I.B., et al. Prostatic acid phosphatase is not a prostate specific target. Cancer Res. 2007, 67:6549-6554.
84. Veeramani S., et al. Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocr. Relat. Can. 2005, 12:805-822.
85. Kiesman W.F., et al. A1 adenosine receptor antagonists, agonists, and allosteric enhancers. Handb. Exp. Pharmacol. 2009, 193:25-58.
86. Schaddelee M.P., et al. Pharmacokinetic/pharmacodynamic modelling of the anti-hyperalgesic and anti-nociceptive effect of adenosine A1 receptor partial agonists in neuropathic pain. Eur. J. Pharmacol. 2005, 514:131-140.
87. van Schaick E.A., et al. Selectivity of action of 8-alkylamino analogues of N6-cyclopentyladenosine in vivo: haemodynamic versus anti-lipolytic responses in rats. Br. J. Pharmacol. 1998, 124:607-618.
88. Maier S.A., et al. Phylogenetic analysis reveals a novel protein family closely related to adenosine deaminase. J. Mol. Evol. 2005, 61:776-794.
89. Iijima R., et al. The extracellular adenosine deaminase growth factor, ADGF/CECR1, plays a role in Xenopus embryogenesis via the adenosine/P1 receptor. J. Biol. Chem. 2008, 283:2255-2264.
90. Zavialov A.V., Engstrom A. Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. Biochem. J. 2005, 391:51-57.
91. Magalhaes-Cardoso M.T., et al. Ecto-AMP deaminase blunts the ATP-derived adenosine A2A receptor facilitation of acetylcholine release at rat motor nerve endings. J. Physiol. 2003, 549:399-408.
92. Golembiowska K., et al. Modulation of adenosine release from rat spinal cord by adenosine deaminase and adenosine kinase inhibitors. Brain Res. 1995, 699:315-320.
93. Parkinson F.E., Geiger J.D. Effects of iodotubercidin on adenosine kinase activity and nucleoside transport in DDT1 MF-2 smooth muscle cells. J. Pharmacol. Exp. Ther. 1996, 277:1397-1401.
94. Sinclair C.J., et al. Nucleoside transporter subtype expression: effects on potency of adenosine kinase inhibitors. Br. J. Pharmacol. 2001, 134:1037-1044.